Zacks: Brokerages Anticipate Uniqure NV (QURE) Will Announce Quarterly Sales of $3.55 Million

Analysts forecast that Uniqure NV (NASDAQ:QURE) will report sales of $3.55 million for the current quarter, Zacks Investment Research reports. Two analysts have provided estimates for Uniqure’s earnings, with estimates ranging from $3.50 million to $3.60 million. Uniqure posted sales of $4.94 million during the same quarter last year, which would indicate a negative year over year growth rate of 28.1%. The firm is scheduled to report its next earnings report on Tuesday, August 14th.

On average, analysts expect that Uniqure will report full year sales of $17.44 million for the current fiscal year, with estimates ranging from $13.98 million to $26.00 million. For the next fiscal year, analysts expect that the firm will report sales of $13.23 million per share, with estimates ranging from $10.00 million to $16.90 million. Zacks’ sales calculations are a mean average based on a survey of sell-side research firms that cover Uniqure.

Get Uniqure alerts:

Uniqure (NASDAQ:QURE) last announced its quarterly earnings results on Monday, April 30th. The biotechnology company reported ($0.59) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.74) by $0.15. The firm had revenue of $3.48 million during the quarter, compared to the consensus estimate of $3.08 million. Uniqure had a negative return on equity of 131.55% and a negative net margin of 586.38%.

A number of brokerages recently issued reports on QURE. ValuEngine raised Uniqure from a “hold” rating to a “buy” rating in a report on Monday, April 2nd. HC Wainwright set a $35.00 price objective on Uniqure and gave the company a “buy” rating in a report on Tuesday, May 1st. Leerink Swann reissued an “outperform” rating and issued a $63.00 price objective (up from $26.00) on shares of Uniqure in a report on Monday, May 7th. BidaskClub downgraded Uniqure from a “buy” rating to a “hold” rating in a report on Saturday, March 17th. Finally, Wells Fargo assumed coverage on Uniqure in a report on Wednesday, May 16th. They issued an “outperform” rating and a $47.00 price objective for the company. Two equities research analysts have rated the stock with a hold rating, seven have given a buy rating and two have given a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $30.88.

In other news, CEO Matthew C. Kapusta sold 39,169 shares of the stock in a transaction that occurred on Thursday, March 15th. The stock was sold at an average price of $21.72, for a total value of $850,750.68. Following the completion of the sale, the chief executive officer now directly owns 439,764 shares of the company’s stock, valued at $9,551,674.08. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.73% of the stock is currently owned by corporate insiders.

Hedge funds and other institutional investors have recently modified their holdings of the stock. Opaleye Management Inc. acquired a new stake in shares of Uniqure during the fourth quarter worth $1,778,000. Royce & Associates LP acquired a new stake in shares of Uniqure during the fourth quarter worth $2,449,000. Victory Capital Management Inc. acquired a new stake in shares of Uniqure during the fourth quarter worth $1,298,000. Perceptive Advisors LLC lifted its holdings in shares of Uniqure by 0.8% during the fourth quarter. Perceptive Advisors LLC now owns 1,047,950 shares of the biotechnology company’s stock worth $20,529,000 after purchasing an additional 7,831 shares during the period. Finally, Tekla Capital Management LLC lifted its holdings in shares of Uniqure by 38.1% during the fourth quarter. Tekla Capital Management LLC now owns 332,850 shares of the biotechnology company’s stock worth $6,521,000 after purchasing an additional 91,829 shares during the period. 43.83% of the stock is owned by hedge funds and other institutional investors.

Uniqure traded up $0.07, reaching $31.38, on Friday, according to Marketbeat. The company’s stock had a trading volume of 14,294 shares, compared to its average volume of 390,560. The company has a quick ratio of 5.48, a current ratio of 5.48 and a debt-to-equity ratio of 0.16. The company has a market capitalization of $1.16 billion, a price-to-earnings ratio of -10.71 and a beta of 0.15. Uniqure has a fifty-two week low of $4.90 and a fifty-two week high of $33.41.

About Uniqure

uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. The company develops AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia; and AMT-126, a gene therapy for the treatment of congestive heart failure and AMT-130 to treat huntington's disease.

Get a free copy of the Zacks research report on Uniqure (QURE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Best Warren Buffett Stocks To Own For 2018

tags:TXMD,KAMN,EHTH,CNR,NDRO,

Apple's vote of confidence from investing icon Warren Buffett is just one sign that the company has entered a new era, Gene Munster told CNBC's "Squawk on the Street" on Monday.

Two things are changing in the "Apple story," according to Munster, formerly a well-known Apple analyst on Wall Street and now a venture investor.

First, Apple's iPhone sales are now relatively steady, which should reduce quarter-to-quarter anxiety, Munster said. Second, Munster said, Apple's strong cash position could signal more buybacks for loyal investors.

"The big picture here is, we're essentially one week into a new type of thinking around the Apple story," said Munster, now a managing partner at venture capital firm Loup Ventures.

Munster's comments come after a big week for Apple investors. The company reported better-than-feared earnings and a $100 billion buyback last week, and that news was quickly followed by an announcement that Buffett's Berkshire Hathaway bought 75 million shares in the first quarter.

Best Warren Buffett Stocks To Own For 2018: TherapeuticsMD, Inc.(TXMD)

Advisors' Opinion:

• [By ]

  TherapeuticsMD (Nasdaq: TXMD) is a pharmaceutical company with an exclusive focus on products for women and advanced hormone therapies. Biotech stocks are often a target for short sellers because of the uncertainty around drug development and approvals.

• [By Ethan Ryder]

  TherapeuticsMD Inc (NASDAQ:TXMD)’s share price was up 6.4% on Friday . The stock traded as high as $6.07 and last traded at $6.02. Approximately 2,747,655 shares were traded during mid-day trading, an increase of 38% from the average daily volume of 1,984,159 shares. The stock had previously closed at $5.66.

Best Warren Buffett Stocks To Own For 2018: Kaman Corporation(KAMN)

Advisors' Opinion:

• [By Shane Hupp]

  Kaman Aircraft (NYSE:KAMN) hit a new 52-week high and low on Wednesday . The stock traded as low as $67.95 and last traded at $68.00, with a volume of 2807 shares traded. The stock had previously closed at $67.07.

Best Warren Buffett Stocks To Own For 2018: eHealth Inc.(EHTH)

Advisors' Opinion:

• [By Lisa Levin] Gainers Genprex, Inc. (NASDAQ: GNPX) jumped 46.7 percent to $16.1331. The low-float small-cap clinical stage gene therapy company saw its stock rally nearly 150 percent from Monday through Thursday. Formal news hasn't been announced this week that would support a triple-digit percentage rally (including more than 200 percent at one point on Thursday) but the quiet period following its initial public offering will expire on May 8. Celyad SA (NASDAQ: CYAD) shares gained 24.7 percent to $36.17. Celyad reported the publication of THINK study case report of CYAD-01 Induced Complete Remission in relapsed/refractory AML patient in haematologica. DMC Global Inc. (NASDAQ: BOOM) shares jumped 23.2 percent to $39.00 after the company reported upbeat Q1 results and issued upbeat Q2 guidance. eHealth, Inc. (NASDAQ: EHTH) gained 21.8 percent to $19.58 as the company posted upbeat Q1 results. Enova International, Inc. (NYSE: ENVA) climbed 20.4 percent to $27.20 following Q1 results. SVB Financial Group (NASDAQ: SIVB) shares jumped 18.2 percent to $304.135 following strong quarterly results. Knowles Corporation (NYSE: KN) gained 13.9 percent to $12.70 as the company reported Q1 results. Zymeworks Inc. (NYSE: ZYME) gained 13.8 percent to $17.36. Cocrystal Pharma, Inc. (NASDAQ: COCP) rose 11.8 percent to $2.336 after declining 25.09 percent on Thursday. ImmunoGen, Inc. (NASDAQ: IMGN) shares surged 11.7 percent to $11.75 after the company announced 'successful completion of interim analysis' for FORWARD I Phase 3 mirvetuximab soravtansine trial. Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX) gained 9.5 percent to $12.70. Expedia Group, Inc. (NASDAQ: EXPE) shares rose 8.5 percent to $115.3801 after the company reported stronger-than-expected earnings for its first quarter on Thursday. Sprint Corporation (NYSE: S) shares rose 8.3 percent to $6.50. The stock moved higher after a Reuters report suggested ongoing merger talks with T-M
• [By Lisa Levin]

  Shares of eHealth, Inc. (NASDAQ: EHTH) got a boost, shooting up 19 percent to $19.04 as the company posted upbeat Q1 results.

  SVB Financial Group (NASDAQ: SIVB) shares were also up, gaining 17 percent to $301.12 following strong quarterly results.

• [By Lisa Levin]

  Shares of eHealth, Inc. (NASDAQ: EHTH) got a boost, shooting up 16 percent to $18.64 as the company posted upbeat Q1 results.

  Enova International, Inc. (NYSE: ENVA) shares were also up, gaining 25 percent to $28.35 following Q1 results.

Best Warren Buffett Stocks To Own For 2018: China Metro-Rural Holdings Limited(CNR)

Advisors' Opinion:

• [By Max Byerly]

  Canadian National Railway (NYSE:CNI) (TSE:CNR) – Cormark raised their Q3 2018 earnings per share (EPS) estimates for Canadian National Railway in a research report issued to clients and investors on Tuesday, April 10th. Cormark analyst D. Tyerman now expects that the transportation company will post earnings per share of $1.15 for the quarter, up from their previous estimate of $1.14.

• [By Shane Hupp]

  Wall Street analysts expect that Canadian National Railway (NYSE:CNI) (TSE:CNR) will announce $1.02 earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Seven analysts have provided estimates for Canadian National Railway’s earnings, with the highest EPS estimate coming in at $1.06 and the lowest estimate coming in at $0.97. Canadian National Railway reported earnings per share of $1.00 in the same quarter last year, which would suggest a positive year over year growth rate of 2%. The company is expected to announce its next quarterly earnings results on Tuesday, July 24th.

Best Warren Buffett Stocks To Own For 2018: Enduro Royalty Trust(NDRO)

Advisors' Opinion:

• [By Lisa Levin]

  Check out these big penny stock gainers and losers

  Losers Jounce Therapeutics, Inc. (NASDAQ: JNCE) fell 32.5 percent to $11.92 in pre-market trading. Jounce Therapeutics reported that data from ongoing ICONIC trial of JTX-2011 will be presented at the ASCO. Acxiom Corporation (NASDAQ: ACXM) fell 10.7 percent to $24.60 in pre-market trading. Acxiom reported stronger-than-expected results for its fourth quarter, but issued weak FY19 guidance. American Public Education, Inc. (NASDAQ: APEI) shares fell 10.7 percent to $35 in pre-market trading. Enduro Royalty Trust (NYSE: NDRO) shares fell 8.5 percent to $3.25 in pre-market trading after tumbling 10.76 percent on Wednesday. NetEase, Inc. (NASDAQ: NTES) fell 8.3 percent to $244.00 in pre-market trading after reporting Q1 results. Aircastle Limited (NYSE: AYR) fell 7.2 percent to $21.30 in pre-market trading after announcing 7.9 million secondary offering of common shares. Boxlight Corporation (NASDAQ: BOXL) shares fell 5.6 percent to $9.29 in pre-market trading after rising 2.29percent on Wednesday. Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI) shares fell 5.3 percent to $3.93 in pre-market trading after rising 5.60 percent on Wednesday. Cisco Systems, Inc. (NASDAQ: CSCO) fell 4 percent to $43.40 in pre-market trading. Cisco reported better-than-expected results for its third quarter. The company sees fourth quarter earnings in the range of 68 cents-70 cents with sales growth of 4-6 percent. Jack in the Box Inc. (NASDAQ: JACK) fell 3.2 percent to $88.45 in pre-market trading after the company reported downbeat results for its second quarter. Comps were down 0.1 percent in the quarter. The company sees third-quarter comps coming in flat to up 1 percent. Children's Place, Inc. (